In PDAC, cancer cells drive chronic activation of PSCs through paracrine signalling involving platelet derived growth factor (PDGF) which drives PSC proliferation, and both transforming growth factor β-1 (TGF-β-1) and fibroblast growth factor 2 (FGF-2) which drive elaboration of an ECM rich in fibronectin and collagens I, III, and IV [37,38,39]. This evidence concerns the gene FGF2 and cancer.